Macmiror Complex

Treatment option:

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Macmiror Complex

Quick Facts

Property	Description
Active ingredient	Nifuratel and Nystatin
Form	Vaginal capsule
Pharmacological class	Polyvalent antimicrobial agent (ATC code G01AX05)
Common use	Local treatment of mixed infections
Origin	Synthetic (Nifuratel) and Biosynthetic (Nystatin)

What is the Composition and Pharmacological Class of Macmiror Complex?

Macmiror Complex is a fixed-dose combination drug classified as a polyvalent antimicrobial agent, a category often reserved for preparations designed for broad clinical reach against common pathogens (WHO ATC code G01AX05). This medicine, typically associated with the pharmaceutical company Polichem, is presented in the dosage form of a vaginal capsule intended for intravaginal administration. The formulation combines two distinct active ingredients: Nifuratel, which is a synthetic Nitrofuran derivative, and Nystatin, a polyene antibiotic derived from a natural source. The design, featuring two agents in one preparation, is clinically recognized for simplifying treatment by addressing both fungal and protozoal/bacterial pathogens simultaneously, a notable differentiation from single-agent topical therapies.

Why is Macmiror Complex a Broad-Spectrum Combination Agent?

The primary therapeutic principle of Macmiror Complex is its broad-spectrum capability, strategically engineered to provide comprehensive local treatment by targeting the main types of pathogens that frequently cause vaginal inflammation. This breadth is achieved because Nifuratel exhibits efficacy against susceptible bacteria and parasitic protozoa, particularly Trichomonas, whereas Nystatin acts specifically against pathogenic fungi, such as Candida albicans. The dual mechanism is supported by pharmacological studies confirming the product's effectiveness against Trichomonas vaginalis infections. By incorporating both agents into a single application, the formulation is uniquely structured to treat mixed infections—a common scenario where diverse microbial groups coexist—ensuring that the initial therapeutic approach is robust against the full spectrum of microbial etiology.

What side effects are possible with Macmiror Complex?

Possible Side Effects and Safety Information

The official safety profile for Macmiror Complex (Nifuratel and Nystatin vaginal capsule) is defined by its topical route of administration and minimal systemic absorption, according to government regulatory documentation. Adverse reactions are primarily related to the application site.

Adverse Reaction Scope

Category	Regulatory Documentation (SmPC-Aligned)
Key adverse reaction categories	Local adverse reactions at the application site and systemic hypersensitivity reactions (allergic response).
Frequency classification	The frequency of all documented adverse reactions is classified as Not Known (cannot be estimated from the available data).
System-organ classes involved	Skin and subcutaneous tissue disorders and Immune system disorders.
Serious adverse reactions	Hypersensitivity reactions, such as urticaria (hives) and rash, are documented systemic reactions.
Safety-related restrictions	Contraindication in individuals with known hypersensitivity to the active substances (Nifuratel or Nystatin) or any of the product's excipients.

Regulatory Safety Summary

Local Adverse Reactions: The most frequently documented effects are local, including pruritus (itching), burning sensation, irritation, and pain at the application site.
Systemic Reactions: The possibility of hypersensitivity reactions, such as urticaria and rash, is documented as a systemic adverse reaction.
Frequency Status: All listed adverse reactions are assigned the regulatory frequency classification of "Not Known".

Connection to the Overall Safety Profile

The official safety information structures the understanding of risks by categorizing most documented adverse reactions as localized application-site effects within the Skin and subcutaneous tissue disorders class. The formal assignment of "Not Known" frequency indicates that while these effects are recognized, their precise rate of occurrence is not statistically defined in the regulatory documents. The profile’s most significant constraint is defined by an official contraindication based on allergic status.

Overdose and Emergency Response

Macmiror Complex Overdose and when to seek help

The regulatory profile for Macmiror Complex overdosage strictly outlines the officially documented manifestations and the mandatory response actions. Given its local administration, the profile is shaped by the negligible systemic risk of its components.

Overdose Scope Summary	Official Documentation
Systemic Risk	Overdosage results in no systemic toxicity due to the negligible absorption of the Nystatin component.
Manifestations	Documented signs include gastrointestinal distress, such as nausea, vomiting, or stomach bloating.
Antidote Status	No specific antidote for the components is known, requiring symptomatic and supportive management.

When to Seek Immediate Medical Help

Immediate medical attention is required for any suspected overdosage. The officially mandated action is to contact a national Poison Control Helpline for specific guidance. Urgent professional assistance must be sought by calling emergency services (e.g., 911 or local equivalent) if the individual exhibits specific, severe, life-threatening clinical signs. These outcomes documented in regulatory summaries include collapse, seizures, trouble breathing, or inability to be awakened. The presence of any severe neurological or respiratory compromise warrants urgent intervention. Official documentation defines the required management as non-specific symptomatic and supportive treatment.

Therapeutic Uses of Macmiror Complex

Macmiror Complex is applied across domains where additional symptomatic support is needed within women’s health to manage conditions of the lower genital tract marked by symptomatic discomfort. The combination is relevant for managing mixed infections, which often require supportive management against multiple microbial agents. This is relevant in conditions characterized by periods of heightened symptoms, such as bacterial vaginosis, vulvovaginal candidiasis, and trichomonal vaginitis. This approach is considered appropriate in clinical settings that involve acute or unstable symptom patterns.

The medication helps address symptom clusters that interfere with daily functioning, such as intense itching, burning, soreness, and abnormal vaginal discharge with associated odor. The use of this treatment in symptomatic phases provides supportive relief when symptoms interfere with routine activities. It is often used when manifestations intensify and require short-term supportive relief.

Quick Fact: Supports Easing Symptoms related to Inflammatory States (Itching and Burning)

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Macmiror Complex — official regulatory information

Eligibility Scope

Classification	Population Status (Official Labeling)
Populations Allowed	Adults for the local treatment of susceptible vulvovaginal infections.
Populations Not Recommended	Lactating women (breastfeeding) and the pediatric population (children/adolescents), as use is generally not established or advised.
Populations Contraindicated	Pregnant women and patients with a known hypersensitivity to the active substances, Nifuratel or Nystatin, or any other excipients.

Age and Physiological State Rules

Adults: Use is established and indicated for this age group.
Pediatric Population: Use is not recommended; safety and efficacy profiles are not established in children.
Pregnancy: The medicine is contraindicated during pregnancy.
Lactation: Use is not recommended while breastfeeding.
Comorbidity Limitations: No specific restrictions for renal or hepatic impairment are documented in the official labeling for the vaginal formulation.

Eligibility-Related Restrictions

Conditional Use: Women of childbearing potential should use barrier contraceptives during treatment. Sexual intercourse should also be avoided, or barrier contraceptives used, and the sexual partner should be considered for treatment to prevent reinfection.

Connection to the overall eligibility profile: The regulatory profile strictly defines eligibility through absolute contraindications for hypersensitivity and pregnancy. Use is established only in adults, while official guidelines state that use is not recommended in the pediatric population or for breastfeeding women. The eligibility criteria are tied to the local nature of the treatment and the systemic potential of the Nifuratel component.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Macmiror Complex (Nifuratel and Nystatin) as presented in government regulatory documents.

Interaction Scope

The primary focus of official regulatory warnings is the potential for systemic interaction stemming from the Nifuratel component. The drug’s interaction profile is notably focused, documenting a single clinically significant interaction based on its potential to alter the exposure of other systemic medicines.

Category	Official Regulatory Statement
Interacting Drug Category	Oral Coumarin Anticoagulants (e.g., Warfarin, Acenocoumarol)
Interaction Outcome	Co-administration may increase the therapeutic efficacy of the anticoagulant agent.
Interaction-Related Restriction	Co-administration requires caution due to the risk of increased anticoagulant effect.
Timing-based Rules	None documented in official regulatory labeling.

Interaction Classifications

Classification Type	Official Regulatory Summary
Interaction Severity	Clinically significant interaction requiring precaution and monitoring.
Substance Interactions	No specific, citable warnings for interactions with food, alcohol, or herbal products are present in the official prescribing information.

Connection to the overall interaction profile: The regulatory documentation for Macmiror Complex specifically highlights the risk of an exposure-modifying interaction when co-administered with Oral Coumarin Anticoagulants, leading to an increase in their effect. Regulatory authorities do not document specific warnings for metabolic, transporter, or timing-based interactions for this product.

Mechanism of Action

The action of this combination medicine is driven by two distinct, yet functionally complementary, mechanisms that target specific classes of susceptible microorganisms.Targeting Microbial DNA and Metabolic PathwaysThe Nifuratel component works via intracellular biotransformation, relying on enzymes within susceptible bacteria and protozoa (like Trichomonas) to convert the drug into highly reactive intermediates. These cytotoxic molecules then inflict damage by binding directly to the pathogen's essential nucleic acids (DNA/RNA) and interfering with key metabolic enzyme systems, leading to the irreversible cessation of replication and microbial death. This mechanism is dependent on metabolic pathways present only within the microbial cell.Fungicidal Action via Direct Cell Membrane DisruptionThe Nystatin component operates by a physical process called membrane permeabilization. It achieves this by selectively binding to ergosterol, a unique structural lipid found in the cell membranes of fungi (Candida). This binding creates channels or pores that severely compromise the membrane's integrity. The resulting efflux of intracellular components (e.g., ions) causes the fungal cell to lose osmotic balance, leading directly to cell lysis and destruction. The two actions exhibit functional complementarity, achieving a broad mechanistic scope strictly localized to the application site.

Dosage and Administration Information

Official Administration Guidelines for Macmiror Complex

Macmiror Complex, a fixed-dose combination of Nifuratel and Nystatin, is a medicine with a defined administration protocol. The instructions below describe the standardized application method.

Instruction Entity	Description
Route of Administration	The drug is intended for intravaginal use only, involving local application to the vaginal area.
Standard Dosing Regimen	The standard adult dose is one vaginal capsule (ovule) daily containing Nifuratel 500 mg and Nystatin 200,000 IU.
Frequency and Timing	Administration is typically scheduled once per day, generally in the evening or before sleep.
Course Duration	The duration of treatment is defined as a fixed course, often six to twelve days of continuous administration.

Procedural Principles

For proper administration, the ovule is inserted deeply into the highest part of the vagina to achieve optimal local contact. The capsule is designed for direct use and requires no prior preparation or dilution. Although the product is indicated for adults, the same dosing schedule typically applies to elderly patients. To maintain the integrity of the treatment course, it is generally recommended that the full course be completed even if symptomatic improvement occurs early.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Macmiror Complex

Evidence for Local Treatment of Mixed Vaginal Infections

Research examined the Nifuratel and Nystatin combination in studies involving mixed vaginal infections, which are conditions involving the presence of multiple types of pathogens, such as bacteria, protozoa, and fungi, at the same time. The studies have typically included a variety of designs, such as Randomized Clinical Trials (RCTs) and various observational studies, focusing on populations studied that were diagnosed with these combined infections.

Researchers examined microbiological status as a primary outcome, monitoring the presence of targeted pathogens after treatment. They also studied clinical signs and symptoms, such as changes in discharge and inflammation. Findings describe patterns observed in these studies, noting measurements related to pathogen status changes and the evolution of symptoms in the populations observed over the short term.

Evidence for use in Trichomonal Vaginitis

The components of this formulation was studied in research examining specific pathogens, including the parasitic protozoan Trichomonas vaginalis. Research examined the drug in settings where this pathogen is present, often as a component of a broader mixed infection. Studies explored the rate of change in the presence of Trichomonas vaginalis, seeking to understand the short-term impact on the presence of the organism.

Evidence for Managing Symptomatic Discomfort

Research specifically monitored the drug in contexts where patients presented with significant outcomes related to physical discomfort, such as intense itching, burning, and soreness. Studies were conducted during periods of increased symptom activity, focusing on episodes where symptoms became more noticeable and disruptive.

⏱️ Long-Term Studies and Follow-up Durations

Research examining the combination generally focuses on short and intermediate time intervals. The follow-up durations were limited in many studies, meaning that the long-term effects of the use of this combination, such as how durable the microbiological change is after many months, are not fully established.

What is Still Uncertain About Macmiror Complex Research

A primary limitation is that long-term outcomes are not well characterized across the research landscape. Comparative evidence, which involves directly comparing the drug to all relevant standard therapies, is lacking in certain areas. While research describes patterns of symptom change and microbial status, these findings contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly or remain symptom-free over long periods.

Key Studies & References ATC Classification Index: G01AX05 (Nifuratel, combinations)

Frequently Asked Questions (FAQ)

Common questions about Macmiror Complex (FAQ)

Q: Can Macmiror Complex affect the reliability of latex condoms or other barrier contraceptives?

A: Official product information notes that Macmiror Complex may damage latex contraceptives, which include certain condoms and diaphragms. Because of this potential for damage, the use of alternative non-latex contraceptive methods is noted in official documentation during the course of treatment.

Q: Does Macmiror Complex contain any known allergens like nuts, gluten, or soy?

A: The official list of inactive ingredients (excipients) for this formulation includes sodium ethyl-4-hydroxybenzoate and sodium propyl-4-hydroxybenzoate. Regulatory documents indicate that these specific excipients may cause allergic reactions, which could potentially be delayed. The full patient leaflet contains the complete list of inactive ingredients for review.

Q: Is Macmiror Complex available over-the-counter (OTC) or is a prescription always required?

A: According to the official marketing authorization status in many regions, Macmiror Complex is generally classified as a prescription-only medicine. This means it typically requires a prescription from a healthcare provider to be dispensed.

Q: Should my male partner be treated at the same time I am using this medication?

A: In cases where the infection being treated involves Trichomonas vaginalis, the simultaneous treatment of the sexual partner is recommended in regulatory sources. This measure is advised to help prevent the risk of reinfection.

Q: Can this medication cause abnormal discharge or residue?

A: As a local vaginal therapy, the medication may result in the presence of discharge or residue following administration. Official safety documentation specifically notes that some users may observe a yellow-brown residue or a temporary discoloration in the urine.

Q: Can I drive or operate machinery while using Macmiror Complex?

A: Regulatory sources state that because Macmiror Complex is for vaginal use only and is minimally absorbed into the bloodstream, it is not expected to affect the ability to drive or use machinery.

How should Macmiror Complex be stored and disposed of?

How to Store and Dispose of Macmiror Complex?

The storage and disposal of Macmiror Complex (Nifuratel/Nystatin vaginal capsules) must strictly follow the conditions defined in the official regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Store below 25 C or 30 C; Do not freeze and do not refrigerate.
Protection	Keep in the original package and store in a dry place protected from light.
Safety	The product must be kept out of the sight and reach of children.

Disposal Instructions

Official instructions mandate that Macmiror Complex should not be disposed of via household waste or wastewater. Unused or expired medication must be returned to a pharmacy or designated collection point for safe disposal as pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.